Adaptimmune Company
![](/files/companies/Adaptimmune.png)
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients
Investors
Headquarters:
Oxton, York, United Kingdom
Industry:
Genomic and Epigenominc Instabillity
Employee Number:
51-100
Estimated Revenue:
Less than $1M
Investors Number:
14
Investment Stage:
N/A
Investor Type:
Company
Funding Status:
IPO
Number Of Exists:
Post-IPO Equity
Technology:
P4 Medicine
Last Funding Type:
Post-IPO Equity
Founded Date:
2008
Total Funding:
$249.5M